



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

SEP - 8 2004

Ms. Cheryl L. Bagwell
Director of Regulatory Affairs
Chattanooga Group
4717 Adams Road
P.O. Box 489
Hixon, Tennessee 37343

Re: K040662

Trade/Device Name: Vectra Genisys Laser System (Intelect XT Laser System)

Regulation Number: 21 CFR 890.5500

Regulation Name: Infrared Lamp

Regulatory Class: II Product Code: ILY Dated: July 22, 2004 Received: July 23, 2004

Dear Ms. Bagwell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Division of General, Restorative and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number	(if known):	K040662 ys Laser System (Intele	ect XT Laser System)
Indications for		ys Laser System (men	cet AT Laser Bystem)
Vectra Ger XT) Laser * tempo * tempo * relaxa * tempo	Transportable orary increase in orary relief of nuttion of muscle orary relief of n	XT) Laser Module and Systems are indicated in local blood circulation in muscle and joint services spasms	Vectra Genisys (Intelect for topical heating for: on aches, pains and stiffness associated with arthritis
		Division of	ign-Off) General, Restorative, ogical Devices
		510(k) Nun	mberK040662
Prescription Use (Per 21 CFR 801 St		AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NO	OT WRITE BELC	OW THIS LINE- CONTIN	UE ON ANOTHER PAGE IF NEEDED)
C	oncurrence of	CDRH, Office of Devi	ce Evaluation (ODE)